Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 14.0

Eligibility Criteria:
Inclusion Criteria:~* Adult participants (≥18 years of age) with a diagnosis of moderate-to-severe chronic plaque psoriasis (defined by ≥10% body surface area \[BSA\] involvement, moderate or greater score on the Physician's Global Assessment \[PGA\] scale, and PASI score ≥12 at Baseline)~* Participants must have a diagnosis of predominantly plaque psoriasis for ≥6 months (as determined by interview and confirmation of diagnosis through physical examination by investigator) and be considered candidates for phototherapy or systemic therapy. Participants with psoriatic arthritis may be included in the study~Exclusion Criteria:~* Nonplaque forms of psoriasis specifically erythrodermic psoriasis, predominantly pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis~* Participants who will require oral or injectable corticosteroids during the trial~* Presence of any infection requiring treatment with systemic antibiotics within 2 weeks prior to Screening, or serious infection (eg, pneumonia, cellulitis, bone or joint infections) requiring hospitalization or treatment with intravenous antibiotics within 8 weeks prior to Screening~* Participants with evidence of active or untreated latent tuberculosis (TB) according to Screening criteria specified in the protocol. (Prophylactic treatment for latent TB as per local guidelines must be initiated at least 4 weeks prior to treatment with study medication)~* Previous exposure to any agents targeting interleukin-12 (IL-12) and/or Interleukin-23 (IL-23)~* Participants with prior exposure to two or more tumor necrosis factor (TNF) antagonists with discontinuation due to lack of efficacy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1: Tildrakizumab 5 mg (Type: EXPERIMENTAL): Participants receive tildrakizumab 5 mg, subcutaneously (SC) at Weeks 0 and 4
- Part 1: Tildrakizumab 25 mg (Type: EXPERIMENTAL): Participants receive tildrakizumab 25 mg, SC, at Weeks 0 and 4
- Part 1: Tildrakizumab 100 mg (Type: EXPERIMENTAL): Participants receive tildrakizumab 100 mg, SC, at Weeks 0 and 4
- Part 1: Tildrakizumab 200 mg (Type: EXPERIMENTAL): Participants receive tildrakizumab 200 mg, SC, at Weeks 0 and 4
- Part 1: Placebo (Type: PLACEBO_COMPARATOR): Participants receive placebo, SC, at Weeks 0 and 4
- Part 2: Tildrakizumab 5 mg (Type: EXPERIMENTAL): Participants receive tildrakizumab 5 mg, SC, every 12 weeks for up to 36 weeks
- Part 2: Tildrakizumab 25 mg (Type: EXPERIMENTAL): Participants receive tildrakizumab 25 mg, SC, every 12 weeks for up to 36 weeks
- Part 2: Tildrakizumab 100 mg (Type: EXPERIMENTAL): Participants receive tildrakizumab 100 mg, SC, every 12 weeks for up to 36 weeks
- Part 2: Tildrakizumab 200 mg (Type: EXPERIMENTAL): Participants receive tildrakizumab 200 mg, SC, every 12 weeks for up to 36 weeks
- Part 3: Tildrakizumab 5 mg Follow-up (Type: NO_INTERVENTION): Participants are followed for up to 20 weeks after the last dose of study drug.
- Part 3: Tildrakizumab 25 mg Follow-up (Type: NO_INTERVENTION): Participants are followed for up to 20 weeks after the last dose of study drug.
- Part 3: Tildrakizumab 100 mg Follow-up (Type: NO_INTERVENTION): Participants are followed for up to 20 weeks after the last dose of study drug.
- Part 3: Tildrakizumab 200 mg Follow-up (Type: NO_INTERVENTION): Participants are followed for up to 20 weeks after the last dose of study drug.
- Part 3: Placebo Follow-up (Type: NO_INTERVENTION): Participants are followed for up to 20 weeks after the last dose of study drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).